AIMS: Pre-clinical data suggest that the racemic phyto-oestrogen 8-prenylnaringenin (8-PN) may have beneficial effects in postmenopausal women and may become an alternative to classical hormone replacement therapy (HRT) treatment regimes. The aim of this study was to investigate the pharmacokinetics, endocrine effects and tolerability of chemically synthesized 8-PN in postmenopausal women. METHODS: The study was performed using a randomized, double-blind, placebo-controlled, dose-escalation design with three groups of eight healthy postmenopausal women. In each group six subjects received 8-PN and two subjects placebo. 8-PN was given orally in doses of 50, 250 or 750 mg. Drug concentrations in serum, urine and faeces were measured up to 48 h and follicle-stimulating hormone/luteinizing hormone (LH) concentrations up to 24 h. RESULTS: All treatments were well tolerated and associated with a low incidence of (drug unrelated) adverse events. Serum concentrations of free 8-PN showed rapid drug absorption and secondary peaks suggestive of marked enterohepatic recirculation. Independent of the treatment group, approximately 30% of the dose was recovered in excreta as free compound or conjugates over the 48-h observation period. The first C(max) and AUC(0-48 h) showed dose linearity with ratios of 1 : 4.5 : 13.6 (C(max)) and 1 : 5.2 : 17.1 (AUC). The750- mg dose decreased LH concentrations by 16.7% (95% confidence interval 0.5, 30.2). CONCLUSION: Single oral doses of up to 750 mg 8-PN were well tolerated by postmenopausal women. The pharmacokinetic profile of 8-PN was characterized by rapid and probably complete enteral absorption, high metabolic stability, pronounced enterohepatic recirculation and tight dose linearity. The decrease in LH serum concentrations found after the highest dose demonstrates the ability of 8-PN to exert systemic endocrine effects in postmenopausal women.
RCT Entities:
AIMS: Pre-clinical data suggest that the racemic phyto-oestrogen 8-prenylnaringenin (8-PN) may have beneficial effects in postmenopausal women and may become an alternative to classical hormone replacement therapy (HRT) treatment regimes. The aim of this study was to investigate the pharmacokinetics, endocrine effects and tolerability of chemically synthesized 8-PN in postmenopausal women. METHODS: The study was performed using a randomized, double-blind, placebo-controlled, dose-escalation design with three groups of eight healthy postmenopausal women. In each group six subjects received 8-PN and two subjects placebo. 8-PN was given orally in doses of 50, 250 or 750 mg. Drug concentrations in serum, urine and faeces were measured up to 48 h and follicle-stimulating hormone/luteinizing hormone (LH) concentrations up to 24 h. RESULTS: All treatments were well tolerated and associated with a low incidence of (drug unrelated) adverse events. Serum concentrations of free 8-PN showed rapid drug absorption and secondary peaks suggestive of marked enterohepatic recirculation. Independent of the treatment group, approximately 30% of the dose was recovered in excreta as free compound or conjugates over the 48-h observation period. The first C(max) and AUC(0-48 h) showed dose linearity with ratios of 1 : 4.5 : 13.6 (C(max)) and 1 : 5.2 : 17.1 (AUC). The750- mg dose decreased LH concentrations by 16.7% (95% confidence interval 0.5, 30.2). CONCLUSION: Single oral doses of up to 750 mg 8-PN were well tolerated by postmenopausal women. The pharmacokinetic profile of 8-PN was characterized by rapid and probably complete enteral absorption, high metabolic stability, pronounced enterohepatic recirculation and tight dose linearity. The decrease in LH serum concentrations found after the highest dose demonstrates the ability of 8-PN to exert systemic endocrine effects in postmenopausal women.
Authors: S R Milligan; J C Kalita; V Pocock; V Van De Kauter; J F Stevens; M L Deinzer; H Rong; D De Keukeleire Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Y Shirataki; N Motohashi; S Tani; H Sakagami; K Satoh; H Nakashima; S K Mahapatra; K Ganguly; S G Dastidar; A N Chakrabarty Journal: Anticancer Res Date: 2001 Jan-Feb Impact factor: 2.480
Authors: H Rong; T Boterberg; J Maubach; C Stove; H Depypere; S Van Slambrouck; R Serreyn; D De Keukeleire; M Mareel; M Bracke Journal: Eur J Cell Biol Date: 2001-09 Impact factor: 4.492
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Selin Bolca; Jinghu Li; Dejan Nikolic; Nathalie Roche; Phillip Blondeel; Sam Possemiers; Denis De Keukeleire; Marc Bracke; Arne Heyerick; Richard B van Breemen; Herman Depypere Journal: Mol Nutr Food Res Date: 2010-07 Impact factor: 5.914
Authors: Elizabeth Krause; Yang Yuan; Atieh Hajirahimkhan; Huali Dong; Birgit M Dietz; Dejan Nikolic; Guido F Pauli; Judy L Bolton; Richard B van Breemen Journal: Biomed Chromatogr Date: 2014-06 Impact factor: 1.902
Authors: Richard B van Breemen; Yang Yuan; Suzanne Banuvar; Lee P Shulman; Xi Qiu; René F Ramos Alvarenga; Shao-Nong Chen; Birgit M Dietz; Judy L Bolton; Guido F Pauli; Elizabeth Krause; Marlos Viana; Dejan Nikolic Journal: Mol Nutr Food Res Date: 2014-09-16 Impact factor: 5.914
Authors: Ryan T Hitzman; Tareisha L Dunlap; Caitlin E Howell; Shao-Nong Chen; Günter Vollmer; Guido F Pauli; Judy L Bolton; Birgit M Dietz Journal: Chem Res Toxicol Date: 2020-10-12 Impact factor: 3.739
Authors: Cassia R Overk; Jian Guo; Lucas R Chadwick; Daniel D Lantvit; Alberto Minassi; Giovanni Appendino; Shao-Nong Chen; David C Lankin; Norman R Farnsworth; Guido F Pauli; Richard B van Breemen; Judy L Bolton Journal: Chem Biol Interact Date: 2008-06-20 Impact factor: 5.192
Authors: Annekathrin M Keiler; Dana Macejova; Birgit M Dietz; Judy L Bolton; Guido F Pauli; Shao-Nong Chen; Richard B van Breemen; Dejan Nikolic; Florian Goerl; Michael H Muders; Oliver Zierau; Günter Vollmer Journal: J Steroid Biochem Mol Biol Date: 2017-09-28 Impact factor: 4.292
Authors: Birgit M Dietz; Ghenet K Hagos; Jillian N Eskra; Gihani T Wijewickrama; Jeffrey R Anderson; Dejan Nikolic; Jian Guo; Brian Wright; Shao-Nong Chen; Guido F Pauli; Richard B van Breemen; Judy L Bolton Journal: Mol Nutr Food Res Date: 2013-03-20 Impact factor: 5.914